Hemostemix's Boots on the Ground in Florida

Core Insights - Hemostemix Inc. is launching a face-to-face sales program in Florida to promote its autologous stem cell therapy, VesCell™ (ACP-01), targeting patients with severe conditions who have exhausted standard treatment options [1][2][3] Company Strategy - The company is implementing a "boots on the ground" strategy, with leadership directly engaging clinicians and clinic owners across Florida to facilitate the adoption of VesCell™ [2][3] - The focus is on building relationships with the clinical community, leveraging prior trial experiences to enhance treatment access [3] Scientific and Clinical Results - Hemostemix has treated 498 patients and completed seven clinical studies involving 318 subjects, resulting in 11 peer-reviewed publications that validate the safety and efficacy of VesCell™ [4] - Clinical results show significant improvements, such as a reduction in ulcer size from a mean of 1.46 cm² to 0.48 mm² in treated patients [10] Regulatory Engagement - The Florida rollout strategy includes data collection to support FDA engagement, enhancing the company's safety and efficacy profile for regulatory approval [5] - The Right-to-Try statute SB 1768 allows physicians to offer VesCell™ to patients suffering from various severe conditions, including Peripheral Arterial Disease and Chronic Limb-Threatening Ischemia [6][7] Treatment Outcomes - VesCell™ has demonstrated the ability to generate new blood vessels, restore circulation, and heal ulcers, with a reported wound healing rate of 83% in patients followed for up to 4.5 years [11][13] - In studies, VesCell™ improved overall ejection fraction, exercise capacity, and quality of life for patients with chronic stable angina [12]